NASDAQ:ATOS - Atossa Genetics News Headlines

Sign in or create an account to add this stock to your watchlist.
$4.04 -0.19 (-4.49 %)
(As of 03/20/2019 04:00 PM ET)
Previous Close$4.23
Today's Range$3.81 - $4.19
52-Week Range$0.80 - $7.56
Volume2.03 million shs
Average Volume3.38 million shs
Market Capitalization$22.81 million
P/E RatioN/A
Dividend YieldN/A
Beta3.59

Headlines

Atossa Genetics (NASDAQ ATOS) News Headlines

Source:
DateHeadline
Atossa Genetics Inc. Estimate MomentumAtossa Genetics Inc. Estimate Momentum
www.nasdaq.com - March 18 at 8:06 PM
Atossa Genetics: Expect More Near-Term Positive Catalysts After Continued FDA Approval For One PatientAtossa Genetics: Expect More Near-Term Positive Catalysts After Continued FDA Approval For One Patient
seekingalpha.com - March 18 at 8:06 PM
Atossa Genetics Announces Receipt of $10 MillionAtossa Genetics Announces Receipt of $10 Million
finance.yahoo.com - March 18 at 8:06 PM
Trade Alert: Long Atossa GeneticsTrade Alert: Long Atossa Genetics
seekingalpha.com - March 15 at 7:35 PM
Zacks: Atossa Genetics Inc (ATOS) Given $7.00 Average Price Target by BrokeragesZacks: Atossa Genetics Inc (ATOS) Given $7.00 Average Price Target by Brokerages
www.americanbankingnews.com - March 15 at 12:49 PM
Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer PatientAtossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient
finance.yahoo.com - March 14 at 7:23 PM
Atossa up 227% premarket on expanded access for EndoxifenAtossa up 227% premarket on expanded access for Endoxifen
seekingalpha.com - March 14 at 7:23 PM
What Type Of Shareholder Owns Atossa Genetics Inc.’s (NASDAQ:ATOS)?What Type Of Shareholder Owns Atossa Genetics Inc.’s (NASDAQ:ATOS)?
finance.yahoo.com - March 14 at 7:23 PM
"On Feds Wings" Vista Partners Publishes February 2019s Macroeconomic & Investment Monthly Newsletter"On Fed's Wings" Vista Partners Publishes February 2019's Macroeconomic & Investment Monthly Newsletter
finance.yahoo.com - February 27 at 8:15 AM
Atossa up 24% on encouraging Endoxifen dataAtossa up 24% on encouraging Endoxifen data
seekingalpha.com - February 7 at 6:47 PM
Atossa Genetics Reports Results From “Expanded Access” Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability IssuesAtossa Genetics Reports Results From “Expanded Access” Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues
finance.yahoo.com - February 7 at 6:47 PM
Atossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task ForceAtossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force
finance.yahoo.com - February 5 at 6:28 AM
Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019
globenewswire.com - January 28 at 6:25 PM
Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019
finance.yahoo.com - January 28 at 8:11 AM
ATOS, NGD among premarket gainersATOS, NGD among premarket gainers
seekingalpha.com - January 9 at 7:06 PM
Atossa Genetics up 41% on completing Phase 1 study of topical Endoxifen in maleAtossa Genetics up 41% on completing Phase 1 study of topical Endoxifen in male
seekingalpha.com - January 9 at 7:06 PM
Atossa Genetics Announces Successful Completion and Final Results from Male Phase 1 Study of Topical EndoxifenAtossa Genetics Announces Successful Completion and Final Results from Male Phase 1 Study of Topical Endoxifen
www.nasdaq.com - January 9 at 7:06 PM
Edison issues outlook on Atossa Genetics (ATOS)Edison issues outlook on Atossa Genetics (ATOS)
finance.yahoo.com - December 7 at 5:44 PM
Atossa Genetics (ATOS) Announces FDA Approval of Endoxifen for Expanded AccessAtossa Genetics (ATOS) Announces FDA Approval of Endoxifen for 'Expanded Access'
www.streetinsider.com - December 3 at 5:19 PM
FDA approves Atossa Genetics endoxifen for “expanded access” as preoperative systemic endocrine therapyFDA approves Atossa Genetics' endoxifen for “expanded access” as preoperative systemic endocrine therapy
seekingalpha.com - December 3 at 5:19 PM
Atossa Genetics Announces FDA Approval  of Endoxifen for “Expanded Access” as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer PatientAtossa Genetics Announces FDA Approval  of Endoxifen for “Expanded Access” as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient
finance.yahoo.com - December 3 at 8:14 AM
Atossa Genetics Announces Third Quarter 2018 Financial Results And Provides Company UpdateAtossa Genetics Announces Third Quarter 2018 Financial Results And Provides Company Update
finance.yahoo.com - November 13 at 5:15 PM
Atossa Genetics (ATOS) Reports Complete Enrollment in Phase 2 Study of Topical EndoxifenAtossa Genetics (ATOS) Reports Complete Enrollment in Phase 2 Study of Topical Endoxifen
www.streetinsider.com - October 12 at 5:07 PM
Atossa Genetics completes enrollment in Phase 2 study of Topical EndoxifenAtossa Genetics completes enrollment in Phase 2 study of Topical Endoxifen
seekingalpha.com - October 11 at 4:54 PM
Atossa Genetics Completes Enrollment in Phase 2 Study of Topical Endoxifen in Women with Mammographic Breast DensityAtossa Genetics Completes Enrollment in Phase 2 Study of Topical Endoxifen in Women with Mammographic Breast Density
finance.yahoo.com - October 11 at 8:14 AM
An Interview with Atossa CEO Steven Quay MD, Ph.D. Titled, "What Is Gynecomastia?"An Interview with Atossa CEO Steven Quay MD, Ph.D. Titled, "What Is Gynecomastia?"
finance.yahoo.com - September 14 at 5:03 PM
Atossa Genetics (ATOS) Announces Preliminary Results from Male Phase 1 Study of Topical EndoxifenAtossa Genetics (ATOS) Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen
www.streetinsider.com - September 13 at 4:57 PM
Atossa Genetics (ATOS) CEO Steve Quay on Preliminary Results from Male Phase 1 Study of Topical Endoxifen Conference (Transcript)Atossa Genetics (ATOS) CEO Steve Quay on Preliminary Results from Male Phase 1 Study of Topical Endoxifen Conference (Transcript)
seekingalpha.com - September 13 at 4:57 PM
Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical EndoxifenAtossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen
finance.yahoo.com - September 13 at 8:18 AM
Atossa conference call tomorrow on Phase 1 results for topical endoxifen; shares up 10% premarketAtossa conference call tomorrow on Phase 1 results for topical endoxifen; shares up 10% premarket
seekingalpha.com - September 12 at 4:53 PM
Atossa Genetics to Host Conference Call to Announce Preliminary Results from Male Phase 1 Study of Topical Endoxifen Thursday, September 13, 2018 at 10 am EDTAtossa Genetics to Host Conference Call to Announce Preliminary Results from Male Phase 1 Study of Topical Endoxifen Thursday, September 13, 2018 at 10 am EDT
finance.yahoo.com - September 12 at 8:16 AM
"What Is Intraductal Immuno-oncology & CAR-T Cell Therapy?""What Is Intraductal Immuno-oncology & CAR-T Cell Therapy?"
finance.yahoo.com - August 21 at 5:01 PM
Atossa Genetics Announces Second Quarter 2018 Financial Results And Provides Company UpdateAtossa Genetics Announces Second Quarter 2018 Financial Results And Provides Company Update
finance.yahoo.com - August 13 at 5:53 PM
Analysis: Positioning to Benefit within Mueller Industries, Eros International, Gannett Co., MarketAxess, Atossa Genetics ...Analysis: Positioning to Benefit within Mueller Industries, Eros International, Gannett Co., MarketAxess, Atossa Genetics ...
globenewswire.com - August 1 at 5:58 PM
The Groundwork Forum Podcast Publishes "An Overview of Breast Cancer Treatment Innovator Atossa Genetics"The Groundwork Forum Podcast Publishes "An Overview of Breast Cancer Treatment Innovator Atossa Genetics"
finance.yahoo.com - August 1 at 5:58 PM
Atossa Genetics Contracts with Additional Manufacturer of EndoxifenAtossa Genetics Contracts with Additional Manufacturer of Endoxifen
finance.yahoo.com - August 1 at 8:14 AM
Analysis: Positioning to Benefit within Mueller Industries, Eros International, Gannett Co., MarketAxess, Atossa Genetics, and McDonalds — Research Highlights Growth, Revenue, and Consolidated ResultsAnalysis: Positioning to Benefit within Mueller Industries, Eros International, Gannett Co., MarketAxess, Atossa Genetics, and McDonald's — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - July 31 at 8:23 AM
Atossa Genetics to advance microcatheter immunotherapy program; shares up 1% premarketAtossa Genetics to advance microcatheter immunotherapy program; shares up 1% premarket
seekingalpha.com - July 18 at 4:54 PM
Atossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical ProgramAtossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program
finance.yahoo.com - July 18 at 8:10 AM
Your Daily Pharma Scoop: Advaxis Trial Cleared, Atossa Trial Proceeds, Amgen Resubmits NDAYour Daily Pharma Scoop: Advaxis Trial Cleared, Atossa Trial Proceeds, Amgen Resubmits NDA
seekingalpha.com - July 16 at 8:07 AM
Atossa Genetics (ATOS) Announces Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast CancerAtossa Genetics (ATOS) Announces Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast Cancer
www.streetinsider.com - July 14 at 3:36 PM
Atossa Genetics opens enrollment in mid-stage study of Endoxifen in breast cancer; shares up 5% premarketAtossa Genetics opens enrollment in mid-stage study of Endoxifen in breast cancer; shares up 5% premarket
seekingalpha.com - July 14 at 3:36 PM
Atossa Genetics Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast CancerAtossa Genetics Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast Cancer
finance.yahoo.com - July 14 at 3:36 PM
Atossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast DensityAtossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast Density
finance.yahoo.com - June 26 at 8:29 AM
Atossa Genetics (ATOS) Reports Completion of Dosing & Clinical Visits in Phase 1 Study of Topical Endoxifen in MenAtossa Genetics (ATOS) Reports Completion of Dosing & Clinical Visits in Phase 1 Study of Topical Endoxifen in Men
www.streetinsider.com - June 22 at 5:46 PM
Atossa up 12% on advancement of early-stage study of EndoxifenAtossa up 12% on advancement of early-stage study of Endoxifen
seekingalpha.com - June 20 at 6:04 PM
Atossa Genetics Completes all Dosing and Clinical Visits in its Phase 1 Study of Topical Endoxifen in MenAtossa Genetics Completes all Dosing and Clinical Visits in its Phase 1 Study of Topical Endoxifen in Men
finance.yahoo.com - June 20 at 8:36 AM
Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory BoardAtossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board
finance.yahoo.com - June 14 at 8:17 AM
Does Atossa Genetics Inc’s (NASDAQ:ATOS) -89.06% Earnings Drop Reflect A Longer Term Trend?Does Atossa Genetics Inc’s (NASDAQ:ATOS) -89.06% Earnings Drop Reflect A Longer Term Trend?
finance.yahoo.com - June 12 at 8:14 AM
Atossa expects gross proceeds of $13.4M from recently expired rights offeringAtossa expects gross proceeds of $13.4M from recently expired rights offering
seekingalpha.com - May 25 at 5:59 PM
This page was last updated on 3/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel